Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

2019-04-01

Haematologica , Volume 104 - Issue 4 p. E151- E153

Additional Metadata
Persistent URL	doi.org/10.3324/haematol.2018.196899, hdl.handle.net/1765/116287
Journal	Haematologica
Organisation	Department of Hematology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Hagenbeek, A, Mooij, H., Zijlstra, J., Lugtenburg, P., van Imhoff, G., Nijland, M, … Kersten, M. J. (2019). Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study. Haematologica, 104(4), E151–E153. doi:10.3324/haematol.2018.196899

Publication